• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基质靶向核成像与放射性药物

Stroma targeting nuclear imaging and radiopharmaceuticals.

作者信息

Shetty Dinesh, Jeong Jae-Min, Shim Hyunsuk

机构信息

Department of Radiology and Imaging Sciences, Emory University, 1701 Uppergate Drive, C5008, Atlanta, GA 30322, USA.

出版信息

Int J Mol Imaging. 2012;2012:817682. doi: 10.1155/2012/817682. Epub 2012 May 21.

DOI:10.1155/2012/817682
PMID:22685650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3364577/
Abstract

Malignant transformation of tumor accompanies profound changes in the normal neighboring tissue, called tumor stroma. The tumor stroma provides an environment favoring local tumor growth, invasion, and metastatic spreading. Nuclear imaging (PET/SPECT) measures biochemical and physiologic functions in the human body. In oncology, PET/SPECT is particularly useful for differentiating tumors from postsurgical changes or radiation necrosis, distinguishing benign from malignant lesions, identifying the optimal site for biopsy, staging cancers, and monitoring the response to therapy. Indeed, PET/SPECT is a powerful, proven diagnostic imaging modality that displays information unobtainable through other anatomical imaging, such as CT or MRI. When combined with coregistered CT data, [(18)F]fluorodeoxyglucose ([(18)F]FDG)-PET is particularly useful. However, [(18)F]FDG is not a target-specific PET tracer. This paper will review the tumor microenvironment targeting oncologic imaging such as angiogenesis, invasion, hypoxia, growth, and homing, and also therapeutic radiopharmaceuticals to provide a roadmap for additional applications of tumor imaging and therapy.

摘要

肿瘤的恶性转化伴随着正常邻近组织(即肿瘤基质)的深刻变化。肿瘤基质提供了有利于局部肿瘤生长、侵袭和转移扩散的环境。核成像(PET/SPECT)可测量人体的生化和生理功能。在肿瘤学中,PET/SPECT对于区分肿瘤与术后改变或放射性坏死、鉴别良性与恶性病变、确定活检的最佳部位、癌症分期以及监测治疗反应特别有用。事实上,PET/SPECT是一种强大的、经过验证的诊断成像方式,可显示通过其他解剖成像(如CT或MRI)无法获得的信息。当与配准的CT数据相结合时,[18F]氟脱氧葡萄糖([18F]FDG)-PET特别有用。然而,[18F]FDG不是一种靶向特异性PET示踪剂。本文将综述针对肿瘤微环境的肿瘤成像,如血管生成、侵袭、缺氧、生长和归巢,以及治疗性放射性药物,为肿瘤成像和治疗的更多应用提供路线图。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/324e7112b24d/IJMI2012-817682.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/2732f35cd4ee/IJMI2012-817682.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/5ceb4c03e6b7/IJMI2012-817682.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/67562a7487fe/IJMI2012-817682.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/135236f1ce20/IJMI2012-817682.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/324e7112b24d/IJMI2012-817682.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/2732f35cd4ee/IJMI2012-817682.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/5ceb4c03e6b7/IJMI2012-817682.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/67562a7487fe/IJMI2012-817682.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/135236f1ce20/IJMI2012-817682.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/705f/3364577/324e7112b24d/IJMI2012-817682.007.jpg

相似文献

1
Stroma targeting nuclear imaging and radiopharmaceuticals.基质靶向核成像与放射性药物
Int J Mol Imaging. 2012;2012:817682. doi: 10.1155/2012/817682. Epub 2012 May 21.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
The impact of F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients.氟代脱氧葡萄糖正电子发射断层扫描对儿科软组织肉瘤患者初始分期和治疗计划的影响。
Pediatr Radiol. 2020 Feb;50(2):252-260. doi: 10.1007/s00247-019-04530-1. Epub 2019 Oct 18.
4
Indirect comparison of the diagnostic performance of F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis.F-FDG PET/CT 与 MRI 鉴别卵巢或附件良恶性肿瘤的诊断性能的间接比较:系统评价和荟萃分析。
BMC Cancer. 2021 Oct 6;21(1):1080. doi: 10.1186/s12885-021-08815-3.
5
Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.全身正电子发射断层扫描/计算机断层扫描(PET/CT)发现的良性、非生理性病变中(18)F-氟脱氧葡萄糖摄取增加:来自四年PET/CT经验的累积数据
Semin Nucl Med. 2007 May;37(3):206-22. doi: 10.1053/j.semnuclmed.2007.01.001.
6
Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.使用联合¹⁸F-氟代脱氧葡萄糖正电子发射断层扫描/磁共振成像技术降低辐射剂量对婴儿和学龄前儿童进行全面肿瘤成像:与¹⁸F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的直接比较。
Invest Radiol. 2016 Jan;51(1):7-14. doi: 10.1097/RLI.0000000000000200.
7
Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.正电子发射断层显像-计算机断层扫描(PET-CT)、单光子发射计算机断层扫描-计算机断层扫描(SPECT-CT)和回旋加速器设施的辐射安全操作
Health Phys. 2008 Nov;95(5):554-70. doi: 10.1097/01.HP.0000327651.15794.f7.
8
PET and PET-CT for evaluation of colorectal carcinoma.正电子发射断层扫描(PET)及正电子发射断层显像/X线计算机体层成像(PET-CT)用于结直肠癌评估
Semin Nucl Med. 2004 Jul;34(3):209-23. doi: 10.1053/j.semnuclmed.2004.03.006.
9
Defining optimal tracer activities in pediatric oncologic whole-body F-FDG-PET/MRI.确定儿科肿瘤全身F-FDG-PET/MRI中的最佳示踪剂活性。
Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2283-2289. doi: 10.1007/s00259-016-3503-5. Epub 2016 Aug 26.
10
Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses.心脏肿块的心脏计算机断层扫描和 18-F 氟脱氧葡萄糖正电子发射断层扫描的诊断准确性。
JACC Cardiovasc Imaging. 2020 Nov;13(11):2400-2411. doi: 10.1016/j.jcmg.2020.03.021. Epub 2020 Jun 17.

引用本文的文献

1
New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.新型正电子发射断层扫描肿瘤成像探针设计与合成的前沿:当前挑战与未来方向
Mol Imaging Biol. 2012 Dec;14(6):653-66. doi: 10.1007/s11307-012-0590-y.

本文引用的文献

1
In vivo evaluation of (111)In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection.(111)铟-二乙三胺五乙酸-N-金属蛋白酶组织抑制因子-2在与HIV感染相关的卡波西肉瘤中的体内评估
Eur J Nucl Med. 2001 Jun;28(6):756-61. doi: 10.1007/s002590100522.
2
Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.肽受体放射性核素治疗对神经内分泌肿瘤中生长抑素受体状态和葡萄糖代谢的影响:Ga-68 DOTANOC PET/CT与F-18 FDG PET/CT的个体内比较
Int J Mol Imaging. 2011;2011:524130. doi: 10.1155/2011/524130. Epub 2011 Nov 9.
3
Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
基于放射性卤代 4-苯胺喹唑啉的表皮生长因子受体酪氨酸激酶抑制剂作为潜在的癌症成像剂。
Nucl Med Biol. 2012 Feb;39(2):247-60. doi: 10.1016/j.nucmedbio.2011.09.001. Epub 2011 Nov 12.
4
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.使用一种(68)Ga 标记的高特异性靶向对比剂进行 CXCR4 表达的 PET。
J Nucl Med. 2011 Nov;52(11):1803-10. doi: 10.2967/jnumed.111.098798.
5
1 World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany.第一届镓-68与肽受体放射性核素治疗(PRRNT)世界大会,2011年6月23日至26日,德国巴特贝卡中心医院
World J Nucl Med. 2011 Jan;10(1):1-2. doi: 10.4103/1450-1147.82105.
6
A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients.141 例 II 期和 III 期结直肠癌预后因素的多变量分析。
Chin Med J (Engl). 2011 Jul;124(14):2132-5.
7
Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.在人源肿瘤异种移植模型中评估 CXCR4 表达的影像学研究:单环酰胺 64Cu-AMD3465 的评价。
J Nucl Med. 2011 Jun;52(6):986-93. doi: 10.2967/jnumed.110.085613.
8
Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.生长抑素受体作为核医学成像和放射性核素治疗的靶点。
J Nucl Med. 2011 Jun;52(6):841-4. doi: 10.2967/jnumed.110.084236. Epub 2011 May 13.
9
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?90Y-DOTATATE 与串联 90Y/177Lu-DOTATATE 放射性核素治疗神经内分泌肿瘤的临床疗效:哪种治疗方案更佳?
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1788-97. doi: 10.1007/s00259-011-1833-x. Epub 2011 May 7.
10
PET imaging of CXCR4 using copper-64 labeled peptide antagonist.使用放射性核素标记的 CXCR4 肽拮抗剂进行 PET 成像。
Theranostics. 2011;1:251-62. doi: 10.7150/thno/v01p0251. Epub 2011 Apr 19.